Affiliation:
1. Research Service St. Louis Veterans Affairs Medical Center St. Louis Missouri USA
2. Department of Surgery, Division of Public Health Sciences, School of Medicine Washington University in St. Louis St. Louis Missouri USA
3. Epidemiology Program, College of Heath Sciences University of Delaware Newark Delaware USA
4. Division of Pharmaceutical Outcomes and Policy Eshelman School of Pharmacy Chapel Hill North Carolina USA
Abstract
AbstractObjectiveTo evaluate the impact of post‐diagnostic metformin or statin use and duration on risk of biochemical recurrence in a racially‐diverse cohort of Veterans.MethodsThe population consisted of men diagnosed with prostate cancer in the Veterans Health Administration and treated with either radical prostatectomy or radiation (Full cohort n = 65,759, Black men n = 18,817, White men n = 46,631, Other = 311). The association between post‐diagnostic (1) metformin and (2) statin use with biochemical recurrence was assessed using multivariable, time‐varying Cox Proportional Hazard Models for the overall cohort and by race. In a secondary analysis, metformin and statin duration were evaluated.ResultsPost‐diagnostic metformin use was not associated with biochemical recurrence (multivariable‐adjusted hazard ratio [aHR]: 1.01; 95% confidence interval [CI]: 0.94, 1.09), with similar results observed for both Black and White men. However, duration of metformin use was associated with a reduced risk of biochemical recurrence in the cohort overall (HR: 0.94; 95% CI: 0.92, 0.95) as well as both Black and White men. By contrast, statin use was associated with a reduced risk of biochemical recurrence (HR: 0.83; 95% CI: 0.79, 0.88) in the overall cohort as well as both White and Black men. Duration of statin use was also inversely associated with biochemical recurrence in all groups.ConclusionPost‐diagnostic metformin and statin use have the potential to prevent biochemical recurrence in men diagnosed with prostate cancer.
Funder
Foundation for Barnes-Jewish Hospital
Alvin J. Siteman Cancer Center
U.S. Department of Defense
Reference31 articles.
1. Survelience Epidemiology and End Results. Cancer Stat Facts: Prostate Cancer. Accessed October 10 2022. https://seer.cancer.gov/statfacts/html/prost.html
2. Management of biochemically recurrent prostate cancer following local therapy;Kolodziej M;Am J Manag Care,2014
3. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions;Paller CJ;Clin Adv Hematol Oncol,2013
4. Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy
5. Metformin and cancer: licence to heal?